CompletedPhase 2

Activity of Mefloquine Against Urinary Schistosomiasis

Gabon65 participantsStarted 2010-05

Plain-language summary

Urinary schistosomiasis is a debilitating disease in Central Africa and pregnant women are frequently suffering from this condition. Mefloquine is currently investigated as preventive treatment against malaria in pregnancy and mefloquine is also known to exert activity against schistosomiasis. The investigators want to test the hypothesis whether mefloquine may active against urinary schistosomiasis when used as preventive treatment against malaria in pregnancy.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women after first trimester and before 28th week of pregnancy * HIV negative * Egg excretion of Schistosoma haematobium (mean \>10 eggs per mL urine) * Asymptomatic (no signs of complicated Schistosomiasis, no severe anemia) * Ability to comply with study protocol Exclusion Criteria: * Intake of anthelminthic or antimalarial drug within 2 months prior to inclusion * Allergy to study drugs

What they're measuring

Reduction of egg excretion

Timeframe: 6 weeks after second IPTp

Trial details

NCT IDNCT01132248

SponsorAlbert Schweitzer Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Urinary Schistosomiasis trials